GlassScriptPhysician profile
Carl Wolnisty
NPI 1912906140
$1,210.77
in general payments reported to CMS, 2019-2025
20 companies · $24.68 in 2025
The $24.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $107 · 2021: $558 · 2022: $127 · 2023: $142 · 2024: $63.40 · 2025: $24.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.21 | 2021 | |
| Novo Nordisk INC | $307.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $111.49 | 2019-2023 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.52 | 2021 | |
| Merck Sharp & Dohme LLC | $40.38 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $37.21 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $36.92 | 2021 | |
| Astellas Pharma US INC | $35.00 | 2023 | Veozah |
| Mylan Specialty L.P. | $34.04 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.51 | 2019 | |
| Qiagen, LLC | $25.52 | 2019-2021 | |
| Glaxosmithkline, LLC. | $20.87 | 2022 | |
| Nevro Corp. | $20.55 | 2019 | |
| Optos, INC. | $19.34 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $17.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.31 | 2023 | |
| Corcept Therapeutics | $14.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.76 | 2019 | |
| Circassia INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Wolnisty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.